3,000 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Martin Worley Group

Martin Worley Group purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 3,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $369,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the period. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $464,000. Franklin Resources Inc. lifted its stake in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after purchasing an additional 48,708 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 13.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after buying an additional 4,332 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,236 shares of company stock worth $3,837,680 in the last quarter. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Up 1.2 %

Shares of Jazz Pharmaceuticals stock opened at $126.44 on Thursday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The stock has a market capitalization of $7.68 billion, a P/E ratio of 17.81, a PEG ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a 50 day moving average price of $132.54 and a two-hundred day moving average price of $122.92.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JAZZ. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.